Accueil   Calls for projects   H2020 Health - Calls 2020 1.1 Personalised medicine (1 step CSA)

H2020 Health – Calls 2020 1.1 Personalised medicine (1 step CSA)

Call 1. Better health and care, economic growth and sustainable health systems
1.1 Personalised medicine (1 step CSA)

Key features of the call for projects

Opening date: June 25th, 2019

Date de clôture : April 7th, 2020

Dimension : Europe

Funding:

Type de financement : Subvention

Thématique(s) médicale(s) : All

Secteur(s) industriel(s) :

SC1-HCO-01-2018-2019-2020: Actions in support of the International Consortium for Personalised Medicine

International aspect: The action should focus on building links with third countries by analysing the potential and advantages of collaboration in personalised medicine (PM) with those countries, studying areas of interest for Europe in PM collaboration and promoting international standards in the field. In particular the uptake of personalised approaches in health systems and healthcare should be addressed, taking into account social, cultural, ethical and legal aspects, health economy issues and equitable healthcare. For the 2018 call, the project should focus on CELAC40 as a group of countries, and for the 2019 call on China. For the 2020 call, the project should focus on countries in Africa41, linking also into the EU-AU (African Union) policy dialogue and taking into account the new Africa-Europa Alliance for Sustainable investment and Jobs. Alignment with activities of the Global Alliance for Chronic Diseases (GACD) and The European and Developing Countries Clinical Trials Partnership (EDCTP) activities should be explored. Special attention should be given to prediction and prevention, and to promoting well-being for all at all ages. Furthermore, the project should seek to integrate local knowledge and practice. Data safety and privacy should be addressed in line with existing standards and legislation. The project should have a duration of at least four years and address sustainability beyond that to ensure longer term structuring effect. Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least one participant based in the international partner region; CELAC (2018 call), China (2019 call) and Africa (2020 call).

SC1-HCO-03-2020: Bridging the divide in health research and innovation – boosting return on investment

Applicants should propose actions that would shift benefiting organisations’ R&I performance and would eventually increase their participation in EU funded collaborative projects. Proposed activities should aim to strengthen research development; improve governance, managerial and administration practices; increase the organisations’ international profile; develop HR policies to attract and retain talents, taking into account gender aspects; and create a culture that rewards scientific performance and innovation. Applicants may propose any actions that contribute towards these goals. Beneficiaries of the activities should be active in the field of health research and innovation and should come from low performing Member States/regions that have identified health R&I as a priority in their Research and Innovation Strategies for Smart Specialisation (RIS3). Applicants shall seek synergies with European Structural and Investment Funds, with European and national research and innovation programmes and if applicable with EEA and Norway grants. Applicants are encouraged to leverage funding of this call with other resources.

SC1-HCO-14-2020: ERA-NET: Sustained collaboration of national and regional programmes in cancer research

The successful proposal should align national, regional research funding programmes on translational cancer research by implementing a transnational call with EU co-funding resulting in grants to third parties. Proposals should pool the necessary financial resources from the participating national (or regional) research programmes as well, where appropriate, leverage resources from pertinent foundations, charities and transnational initiatives, with a view to implementing a joint call for proposals resulting in grants to third parties with EU co-funding in this area. The proposal should overcome hurdles that impede long-term coordination, involving research and innovation and cancer care stakeholders, taking into account relevant cancer research and innovation and cancer care initiatives. The proposal should build on previous EU-funded ERA-NET initiatives in this area. The proposal should also demonstrate potential impact at national, regional and transnational research and innovation programmes as well as a leverage effect on national and European research and competitiveness using key indicators. Other joint activities may include: analyses of research and innovation funding and impact, dissemination, communication towards citizens, training, and are requested to include other additional joint transnational calls (without EU co-funding). The proposal should demonstrate that these co-funded other activities exclude any overlaps with related on-going actions co-funded by the EU under Horizon 2020 SC1. Participation of legal entities from third countries, and/or regions including those not automatically eligible for funding in accordance with General Annex A, is encouraged in the joint call as well as in other joint activities including additional joint calls without EU cofunding. Participants from countries not listed in General Annex A are eligible for EU funding under this topic and may request a Union contribution (on the basis of the ERA-NET unit cost) only for the coordination costs of additional activities. The proposal should demonstrate that these co-funded other activities exclude any overlaps with related on-going actions cofunded by the EU under Horizon 2020.

SC1-HCO-16-2020: ERA-NET: Sustained collaboration of national and regional programmes in research on brain-related diseases and disorders of the nervous system

Proposals should demonstrate the potential to coordinate in a sustained manner national and regional research programmes in the area of brain-related diseases, excluding neurodegenerative diseases, by implementing transnational calls with EU co-funding resulting in grants to third parties. Proposed activities should promote wider collaboration between funded ERA-Net projects stemming from the same transnational call but also with relevant projects from other ERANet calls and pertinent H2020-funded projects and international partners active in this field of research. More comprehensive and wider data sharing and early consideration of translational pathways should be inherent requirements for the translational calls to be launched by the ERA-Net. Proposals should pool the necessary financial resources from the participating national (or regional) research programmes as well, where appropriate, leverage resources from pertinent foundations, charities and transnational initiatives, with a view to implementing a joint call for proposals resulting in grants to third parties with EU co-funding in this area. Proposal are requested to implement other joint activities including additional joint calls without EU co-funding. The proposal should demonstrate that these co-funded other activities exclude any overlaps with related on-going actions co-funded by the EU under Horizon 2020.Proposals should engage with key stakeholders, including complementary ERA-Nets, competence partners on regulatory and guidelines issues. Collaboration with the EU funded European Brain Research Area Coordination and Support Action should be foreseen and integrated into the joint programming concept pursued by the funded ERA-Net project.

SC1-HCO-17-2020: Coordinating and supporting research on the human microbiome in Europe and beyond

Scope: Proposals should aim for synergistic collaboration and agreement across various research and innovation programmes on the human microbiome, in Europe and worldwide, dealing with sample collection, processing, standardisation and healthy states references at different sites of the human body (not only one organ), including also interaction with omics, impact of drugs, nutritional and environmental aspects as well as sex and gender differences.
In particular, they should support the agreement of concrete references of healthy human metagenomes across various different populations. Proposals should map the progress and the state of play for specific disease and health issues as well as the success and meaningfulness in different countries. They should propose concrete and strategic research actions on the human microbiome addressing gaps, emerging fields and political priorities. They should complement, support and enhance cooperation in similar activities within Europe and beyond. In line with the strategy for EU international cooperation in research and innovation (COM(2012)497), international cooperation is encouraged with relevant partners from outside the EU. Proposals should cover the whole spectrum of human microbiome research from patient data collection all the way to study reporting in publications, social, ethical and legal
aspects. Proposals should avoid networking without output and provide appropriate indicators to measure its progress and impact.

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree